These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24002735)

  • 21. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
    Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
    Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The role of / 18FDG PET/CT for the initial staging and therapy in primary breast cancer].
    Inokuchi M; Furukawa H; Kayahara M; Ohta T; Kawashima H; Taki J; Kinuya S
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2526-31. PubMed ID: 20009451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-FDG PET/CT for staging of penile cancer.
    Scher B; Seitz M; Reiser M; Hungerhuber E; Hahn K; Tiling R; Herzog P; Reiser M; Schneede P; Dresel S
    J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy.
    Javid S; Segara D; Lotfi P; Raza S; Golshan M
    Ann Surg Oncol; 2010 Jul; 17(7):1841-6. PubMed ID: 20143266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
    Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
    Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.
    Koolen BB; Donker M; Straver ME; van der Noordaa MEM; Rutgers EJT; Valdés Olmos RA; Vrancken Peeters MJTFD
    Br J Surg; 2017 Aug; 104(9):1188-1196. PubMed ID: 28524246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer.
    Abramson RG; Lambert KF; Jones-Jackson LB; Arlinghaus LR; Williams J; Abramson VG; Chakravarthy AB; Yankeelov TE
    Acad Radiol; 2015 Jul; 22(7):853-9. PubMed ID: 25865435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positron emission tomography/computed tomography in locally advanced breast cancer.
    Ozkan E
    Exp Oncol; 2013 Dec; 35(4):253-7. PubMed ID: 24382434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-sectional imaging to evaluate the extent of regional nodal disease in breast cancer patients undergoing neoadjuvant systemic therapy.
    Anderson TL; Glazebrook KN; Murphy BL; Viers LD; Hieken TJ
    Eur J Radiol; 2017 Apr; 89():163-168. PubMed ID: 28267534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early and delayed prediction of axillary lymph node neoadjuvant response by (18)F-FDG PET/CT in patients with locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón Á; León Martín A; Relea Calatayud F; Muñoz Sánchez Mdel M; Cruz Mora MÁ; Jiménez Londoño GA; Espinosa Aunión R
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1309-18. PubMed ID: 24744045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.
    Straver ME; Aukema TS; Olmos RA; Rutgers EJ; Gilhuijs KG; Schot ME; Vogel WV; Peeters MJ
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1069-76. PubMed ID: 20130860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.
    Rousseau C; Devillers A; Campone M; Campion L; Ferrer L; Sagan C; Ricaud M; Bridji B; Kraeber-Bodéré F
    Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1029-36. PubMed ID: 21308372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The value of 18F-FDG PET/CT imaging in breast cancer staging.
    Yararbas U; Avci NC; Yeniay L; Argon AM
    Bosn J Basic Med Sci; 2018 Feb; 18(1):72-79. PubMed ID: 28763628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Groheux D; Giacchetti S; Delord M; de Roquancourt A; Merlet P; Hamy AS; Espié M; Hindié E
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):377-85. PubMed ID: 25432784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography.
    Inoue T; Yutani K; Taguchi T; Tamaki Y; Shiba E; Noguchi S
    J Cancer Res Clin Oncol; 2004 May; 130(5):273-8. PubMed ID: 14986112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy.
    Xin F; Yu Y; Yang ZJ; Hou LK; Mao JF; Xia L; Wang X; Cao XC
    Tumour Biol; 2016 Jun; 37(6):8445-54. PubMed ID: 26733172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two cases of occult breast cancer in which PET-CT was helpful in identifying primary tumors.
    Takabatake D; Taira N; Aogi K; Ohsumi S; Takashima S; Inoue T; Nishimura R
    Breast Cancer; 2008; 15(2):181-4. PubMed ID: 18274836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of FDG PET/CT to Evaluation of Axillary Lymph Nodes after Neoadjuvant Chemotherapy in Breast Cancer.
    Simsek ET; Coban E; Atag E; Gungor S; Sari M; Gurleyik G
    J Coll Physicians Surg Pak; 2021 Jul; 31(7):792-797. PubMed ID: 34271778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.